#1 Clinical Trials Search in Europe

Isavuconazonium Sulfate

Isavuconazonium sulfate, marketed under the brand name Cresemba, is an antifungal medication being studied in various clinical trials. These trials aim to evaluate its safety, efficacy, and pharmacokinetics in treating invasive fungal infections, particularly in patients with compromised immune systems. The drug is being tested in both oral and intravenous formulations across different age groups, including pediatric patients and adults.

Table of Contents

What is Isavuconazonium Sulfate?

Isavuconazonium sulfate is an antifungal medication used to treat serious fungal infections. It’s also known by the brand name Cresemba[1]. This drug belongs to a class of medications called triazole antifungals, which work by stopping the growth of fungi that cause infections[2].

Isavuconazonium sulfate is actually a “prodrug,” which means it’s inactive when you take it. Once in your body, it’s converted to its active form called isavuconazole. This active form is what fights the fungal infections[3].

What is Isavuconazonium Sulfate Used For?

Isavuconazonium sulfate is primarily used to treat two types of serious fungal infections:

  • Invasive Aspergillosis: This is a serious infection caused by a type of mold called Aspergillus. It most often affects the lungs but can spread to other parts of the body[1].
  • Invasive Mucormycosis: Also known as “black fungus,” this is a rare but very serious infection caused by a group of molds called mucormycetes[1].

These infections are particularly dangerous for people with weakened immune systems, such as those undergoing chemotherapy for cancer or those who have had organ transplants[4].

How is Isavuconazonium Sulfate Administered?

Isavuconazonium sulfate can be given in two ways:

  1. Intravenously (IV): This means it’s given directly into a vein through a needle or catheter. This method is often used when starting treatment or for patients who are very ill[1].
  2. Orally: The medication also comes in capsule form that can be taken by mouth[1].

The typical treatment schedule involves a “loading dose” phase followed by a “maintenance dose” phase:

  • Loading dose: The medication is given every 8 hours for the first two days. This helps to quickly build up the amount of medication in your body[1].
  • Maintenance dose: After the first two days, the medication is usually given once daily[1].

The length of treatment can vary depending on the type and severity of the infection, but it may last for several weeks or even months[1].

Effectiveness of Isavuconazonium Sulfate

Clinical trials have shown that isavuconazonium sulfate is effective in treating invasive fungal infections. In one study, it was found to be as effective as other commonly used antifungal medications for treating invasive aspergillosis[4].

The effectiveness of the treatment is usually assessed by looking at several factors:

  • Clinical response: This involves checking if the symptoms of the infection are improving[5].
  • Mycological response: This involves testing to see if the fungus causing the infection is still present[5].
  • Radiological response: This involves using imaging tests like X-rays or CT scans to see if the infection in the lungs or other organs is improving[5].

Safety and Side Effects

Like all medications, isavuconazonium sulfate can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Changes in liver function tests

These side effects are usually monitored closely by healthcare providers during treatment[5]. It’s important to report any unusual symptoms or side effects to your doctor promptly.

Use in Special Populations

Research is ongoing to understand how isavuconazonium sulfate can be used in different groups of patients:

  • Children: Studies are being conducted to determine the safety and correct dosing of isavuconazonium sulfate in pediatric patients[1].
  • Patients with kidney problems: Unlike some other antifungal medications, isavuconazonium sulfate may be safe to use in patients with kidney impairment[5].

Ongoing Research

Scientists continue to study isavuconazonium sulfate to better understand how it works and how it can be used most effectively. Some areas of ongoing research include:

  • Using isavuconazonium sulfate to prevent fungal infections in high-risk patients, such as those undergoing stem cell transplants[4].
  • Studying how the body processes and eliminates the drug, which can help in determining the best dosing strategies[6].
  • Investigating its effectiveness against rare fungal infections[5].

As research continues, our understanding of how to best use isavuconazonium sulfate to fight serious fungal infections will continue to improve.

Aspect Details
Drug Name Isavuconazonium Sulfate (Brand name: Cresemba)
Drug Class Antifungal, Mold-Active Triazole
Primary Uses Treatment and prevention of invasive fungal infections, particularly invasive aspergillosis and mucormycosis
Administration Routes Oral (capsules) and Intravenous (IV infusion)
Patient Populations Adults, pediatric patients (ages 1 to <18 years), immunocompromised patients
Key Study Objectives Safety, efficacy, pharmacokinetics, bioequivalence of different formulations
Notable Trial Types Single and multiple dose studies, mass balance studies, prophylaxis in stem cell transplant patients
Outcome Measures Treatment-emergent adverse events, all-cause mortality, clinical response, radiological response, pharmacokinetic parameters

FAQ

  • What is Isavuconazonium Sulfate used for? Isavuconazonium Sulfate is an antifungal medication used to treat invasive fungal infections, particularly invasive aspergillosis and invasive mucormycosis. It is being studied in clinical trials for its effectiveness in preventing and treating these serious infections, especially in patients with weakened immune systems.
  • How is Isavuconazonium Sulfate administered? Isavuconazonium Sulfate can be administered both orally (as capsules) and intravenously (as an infusion). The specific method of administration may depend on the patient's age, condition, and the particular clinical trial protocol.
  • What are the main goals of the clinical trials involving Isavuconazonium Sulfate? The main goals of these clinical trials are to evaluate the safety, efficacy, and pharmacokinetics of Isavuconazonium Sulfate. Researchers are studying how the drug behaves in the body, its effectiveness in treating or preventing fungal infections, and any potential side effects or safety concerns.
  • Are there any studies involving Isavuconazonium Sulfate in children? Yes, there are clinical trials specifically designed to study Isavuconazonium Sulfate in pediatric patients. These trials aim to determine appropriate dosing, safety, and effectiveness of the drug in children of various age groups, from 1 year old to under 18 years of age.
  • What types of patients are typically included in these clinical trials? The clinical trials involve a range of participants, including healthy volunteers for pharmacokinetic studies, patients with hematological malignancies or those undergoing stem cell transplants who are at risk for fungal infections, and individuals with confirmed invasive fungal infections such as invasive aspergillosis or mucormycosis.

Ongoing Clinical Trials on Isavuconazonium Sulfate

  • Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Greece Italy +2

  • Study on the Effects of Methylprednisolone and Isavuconazonium Sulfate in Immunocompromised Patients with Acute Respiratory Failure of Unknown Cause

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Isavuconazonium Sulfate: An antifungal medication used to treat invasive fungal infections. It is the prodrug of isavuconazole, which is the active form of the medication in the body.
  • Invasive Aspergillosis (IA): A serious fungal infection caused by Aspergillus species, typically affecting the lungs and potentially spreading to other organs in people with weakened immune systems.
  • Invasive Mucormycosis (IM): A rare but life-threatening fungal infection caused by molds of the order Mucorales, often affecting patients with compromised immune systems.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioequivalence: The property of two drug products having the same rate and extent of absorption when administered at the same dose under similar conditions.
  • Loading Dose: An initial higher dose of a medication given at the beginning of a course of treatment to rapidly achieve therapeutic drug levels.
  • Maintenance Dose: The amount of a medication given to maintain steady therapeutic levels in the body after the loading dose.
  • Therapeutic Drug Monitoring (TDM): The practice of measuring specific drug concentrations in a patient's bloodstream at designated intervals to maintain a constant concentration in the blood.
  • Allogeneic Hematopoietic Stem Cell Transplant (HCT): A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor to replace damaged or diseased cells in the bone marrow.
  • Mold-Active Triazoles (MATs): A class of antifungal medications that are effective against mold infections, including drugs like isavuconazole, voriconazole, and posaconazole.

References

  1. https://clinicaltrials.gov/study/NCT03816176
  2. https://clinicaltrials.gov/study/NCT04096157
  3. https://clinicaltrials.gov/study/NCT03241550
  4. https://clinicaltrials.gov/study/NCT03149055
  5. https://clinicaltrials.gov/study/NCT00634049
  6. https://clinicaltrials.gov/study/NCT01813461